However,

0

%

of HCPs agree that even one case of meningococcal disease is too many.5†

†Based on an independent online survey of 500 HCPs.5

help protect eligible older adolescents from the 5 leading meningococcal serogroupshelp protect eligible older adolescents from the 5 leading meningococcal serogroups

Help them get the protection they need. Vaccinate all eligible teens against all 5 leading meningococcal serogroups.2-4‡

Icon for gaps in vaccine coverage against the 5 leading serogroups leaves many teens at risk for meningococcal disease

Gaps in Coverage

Gaps in coverage against all 5 leading serogroups leave most older adolescents at risk1,4

See More

icon for why MenABCWY coverage is important

Why All 5 Serogroups?

See why MenABCWY coverage at age 16 is so important2,6

See More

icon for why meningococcal disease is so dangerous and why vaccine coverage gaps can be deadly

Disease Severity

The consequences of coverage gaps can be deadly7-9

See More

‡ACIP recommends routine administration of a MenACWY vaccine for all healthy persons aged 11 to 18 years, with a single dose at age 11 or 12, followed by a booster dose at age 16. ACIP also recommends a 2-dose MenB vaccine series administered 1 to 6 months apart for healthy persons aged 16 to 23 years on the basis of shared clinical decision-making, with a preferred age range of 16 to 18. For further guidance on individuals in older age groups or at increased risk, see ACIP Meningococcal Vaccine Recommendations.3

ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention; HCP=healthcare professional; Ipsos=Institut Public de Sondage d'Opinion Secteur.

References

  1. Pingali C, Yankey D, Elam-Evans LD, et al. Vaccination coverage among adolescents aged 13–17 years—National Immunization Survey–Teen, United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(34):912-919.

  2. Vaccines and preventable diseases: meningococcal vaccination. Centers for Disease Control and Prevention. Last reviewed October 12, 2021. Accessed August 2, 2023. https://www.cdc.gov/vaccines/vpd/mening/index.html

  3. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1-41.

  4. Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019;134:103571.

  5. Data on file. Pfizer; 2023.

  6. Meningococcal disease: surveillance data tables. Centers for Disease Control and Prevention. Last reviewed July 10, 2023. Accessed September 11, 2023. https://www.cdc.gov/meningococcal/surveillance/surveillance-data.html

  7. Meningococcal disease: diagnosis, treatment, and complications. Centers for Disease Control and Prevention. Last reviewed February 7, 2022. Accessed March 21, 2023. https://www.cdc.gov/meningococcal/about/diagnosis-treatment.html

  8. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-191.

  9. Meningitis. World Health Organization. Accessed April 27, 2023. https://www.who.int/health-topics/meningitis#tab=tab_2